Diagnostic utility of tomographic myocardial perfusion imaging with technetium 99m furifosmin (Q12) compared with thallium 201

Results of a phase III multicenter trial

Robert Hendel, Mario S. Verani, D. Douglas Miller, Frans J Th Wackers, Michael McMahon, Manuel D. Cerqueira, Elias H. Botvinick, Larry Kvols, Myron C. Gerson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Based on physical properties, 99mTc-labeled perfusion agents offer several advantages over 201Tl for myocardial perfusion imaging. The results of in vivo and experimental studies, along with preliminary experience in human subjects, have shown 99mTc-labeled furifosmin to be a promising new perfusion tracer. The purpose of this study was to evaluate the safety of a new myocardial perfusion agent, 99mTc-labeled furifosmin (Q12), and determine the concordance of furifosmin perfusion scintigraphy to 201Tl imaging. In addition, we sought to determine the normalcy rate of myocardial scintigraphy with furifosmin. Methods and Results: One hundred fifty patients constituted the study group in this multicenter trial. Patients underwent exercise testing with furifosmin injected at peak exercise, and tomographic imaging was begun 15 to 30 minutes afterward. After a separate injection, resting images were obtained 3 to 4 hours later. Thallium scintigraphy was performed within 2 weeks of the furifosmin scans, after a similar exercise workload. Patients with a low likelihood of coronary artery disease (n=39) also underwent furifosmin imaging. All images were processed and displayed in uniform manner and interpreted by a panel of readers. No adverse effects or clinically important laboratory alterations were related to furifosmin imaging. Image quality was slightly better with furifosmin than with thallium. The overall concordance between the perfusion studies was 86% (kappa value=0.669). The normalcy rate for furifosmin scintigraphy was 100%. Conclusions: 99mTc-labeled furifosmin is a promising new 99mTc-labeled myocardial perfusion agent, providing diagnostic results similar to those obtained with 201Tl.

Original languageEnglish
Pages (from-to)291-300
Number of pages10
JournalJournal of Nuclear Cardiology
Volume3
Issue number4
DOIs
StatePublished - Jul 1 1996
Externally publishedYes

Fingerprint

Myocardial Perfusion Imaging
Thallium
Multicenter Studies
Perfusion
Exercise
Radionuclide Imaging
Perfusion Imaging
Workload
Coronary Artery Disease
technetium Tc 99m Q12
Safety
Injections

Keywords

  • diagnosis
  • furifosmin
  • radionuclide imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Diagnostic utility of tomographic myocardial perfusion imaging with technetium 99m furifosmin (Q12) compared with thallium 201 : Results of a phase III multicenter trial. / Hendel, Robert; Verani, Mario S.; Miller, D. Douglas; Wackers, Frans J Th; McMahon, Michael; Cerqueira, Manuel D.; Botvinick, Elias H.; Kvols, Larry; Gerson, Myron C.

In: Journal of Nuclear Cardiology, Vol. 3, No. 4, 01.07.1996, p. 291-300.

Research output: Contribution to journalArticle

Hendel, Robert ; Verani, Mario S. ; Miller, D. Douglas ; Wackers, Frans J Th ; McMahon, Michael ; Cerqueira, Manuel D. ; Botvinick, Elias H. ; Kvols, Larry ; Gerson, Myron C. / Diagnostic utility of tomographic myocardial perfusion imaging with technetium 99m furifosmin (Q12) compared with thallium 201 : Results of a phase III multicenter trial. In: Journal of Nuclear Cardiology. 1996 ; Vol. 3, No. 4. pp. 291-300.
@article{80f643e8f9a24762899772fb0e5d548f,
title = "Diagnostic utility of tomographic myocardial perfusion imaging with technetium 99m furifosmin (Q12) compared with thallium 201: Results of a phase III multicenter trial",
abstract = "Background: Based on physical properties, 99mTc-labeled perfusion agents offer several advantages over 201Tl for myocardial perfusion imaging. The results of in vivo and experimental studies, along with preliminary experience in human subjects, have shown 99mTc-labeled furifosmin to be a promising new perfusion tracer. The purpose of this study was to evaluate the safety of a new myocardial perfusion agent, 99mTc-labeled furifosmin (Q12), and determine the concordance of furifosmin perfusion scintigraphy to 201Tl imaging. In addition, we sought to determine the normalcy rate of myocardial scintigraphy with furifosmin. Methods and Results: One hundred fifty patients constituted the study group in this multicenter trial. Patients underwent exercise testing with furifosmin injected at peak exercise, and tomographic imaging was begun 15 to 30 minutes afterward. After a separate injection, resting images were obtained 3 to 4 hours later. Thallium scintigraphy was performed within 2 weeks of the furifosmin scans, after a similar exercise workload. Patients with a low likelihood of coronary artery disease (n=39) also underwent furifosmin imaging. All images were processed and displayed in uniform manner and interpreted by a panel of readers. No adverse effects or clinically important laboratory alterations were related to furifosmin imaging. Image quality was slightly better with furifosmin than with thallium. The overall concordance between the perfusion studies was 86{\%} (kappa value=0.669). The normalcy rate for furifosmin scintigraphy was 100{\%}. Conclusions: 99mTc-labeled furifosmin is a promising new 99mTc-labeled myocardial perfusion agent, providing diagnostic results similar to those obtained with 201Tl.",
keywords = "diagnosis, furifosmin, radionuclide imaging",
author = "Robert Hendel and Verani, {Mario S.} and Miller, {D. Douglas} and Wackers, {Frans J Th} and Michael McMahon and Cerqueira, {Manuel D.} and Botvinick, {Elias H.} and Larry Kvols and Gerson, {Myron C.}",
year = "1996",
month = "7",
day = "1",
doi = "10.1016/S1071-3581(96)90088-4",
language = "English",
volume = "3",
pages = "291--300",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Diagnostic utility of tomographic myocardial perfusion imaging with technetium 99m furifosmin (Q12) compared with thallium 201

T2 - Results of a phase III multicenter trial

AU - Hendel, Robert

AU - Verani, Mario S.

AU - Miller, D. Douglas

AU - Wackers, Frans J Th

AU - McMahon, Michael

AU - Cerqueira, Manuel D.

AU - Botvinick, Elias H.

AU - Kvols, Larry

AU - Gerson, Myron C.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - Background: Based on physical properties, 99mTc-labeled perfusion agents offer several advantages over 201Tl for myocardial perfusion imaging. The results of in vivo and experimental studies, along with preliminary experience in human subjects, have shown 99mTc-labeled furifosmin to be a promising new perfusion tracer. The purpose of this study was to evaluate the safety of a new myocardial perfusion agent, 99mTc-labeled furifosmin (Q12), and determine the concordance of furifosmin perfusion scintigraphy to 201Tl imaging. In addition, we sought to determine the normalcy rate of myocardial scintigraphy with furifosmin. Methods and Results: One hundred fifty patients constituted the study group in this multicenter trial. Patients underwent exercise testing with furifosmin injected at peak exercise, and tomographic imaging was begun 15 to 30 minutes afterward. After a separate injection, resting images were obtained 3 to 4 hours later. Thallium scintigraphy was performed within 2 weeks of the furifosmin scans, after a similar exercise workload. Patients with a low likelihood of coronary artery disease (n=39) also underwent furifosmin imaging. All images were processed and displayed in uniform manner and interpreted by a panel of readers. No adverse effects or clinically important laboratory alterations were related to furifosmin imaging. Image quality was slightly better with furifosmin than with thallium. The overall concordance between the perfusion studies was 86% (kappa value=0.669). The normalcy rate for furifosmin scintigraphy was 100%. Conclusions: 99mTc-labeled furifosmin is a promising new 99mTc-labeled myocardial perfusion agent, providing diagnostic results similar to those obtained with 201Tl.

AB - Background: Based on physical properties, 99mTc-labeled perfusion agents offer several advantages over 201Tl for myocardial perfusion imaging. The results of in vivo and experimental studies, along with preliminary experience in human subjects, have shown 99mTc-labeled furifosmin to be a promising new perfusion tracer. The purpose of this study was to evaluate the safety of a new myocardial perfusion agent, 99mTc-labeled furifosmin (Q12), and determine the concordance of furifosmin perfusion scintigraphy to 201Tl imaging. In addition, we sought to determine the normalcy rate of myocardial scintigraphy with furifosmin. Methods and Results: One hundred fifty patients constituted the study group in this multicenter trial. Patients underwent exercise testing with furifosmin injected at peak exercise, and tomographic imaging was begun 15 to 30 minutes afterward. After a separate injection, resting images were obtained 3 to 4 hours later. Thallium scintigraphy was performed within 2 weeks of the furifosmin scans, after a similar exercise workload. Patients with a low likelihood of coronary artery disease (n=39) also underwent furifosmin imaging. All images were processed and displayed in uniform manner and interpreted by a panel of readers. No adverse effects or clinically important laboratory alterations were related to furifosmin imaging. Image quality was slightly better with furifosmin than with thallium. The overall concordance between the perfusion studies was 86% (kappa value=0.669). The normalcy rate for furifosmin scintigraphy was 100%. Conclusions: 99mTc-labeled furifosmin is a promising new 99mTc-labeled myocardial perfusion agent, providing diagnostic results similar to those obtained with 201Tl.

KW - diagnosis

KW - furifosmin

KW - radionuclide imaging

UR - http://www.scopus.com/inward/record.url?scp=0029765521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029765521&partnerID=8YFLogxK

U2 - 10.1016/S1071-3581(96)90088-4

DO - 10.1016/S1071-3581(96)90088-4

M3 - Article

VL - 3

SP - 291

EP - 300

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

SN - 1071-3581

IS - 4

ER -